PECULIARITIES OF CHRONIC MYELOID LEUKEMIA INCIDENCE IN THE ALTAi krai
https://doi.org/10.15372/SSMJ20190214
Abstract
The purpose of research is to estimate disease incidence for chronic myeloid leukemia in the Altay Region. Material and methods. The absolute morbidity rate of chronic myeloid leukemia in the Altai Region (primary disease incidence), as well as the intensive morbidity rate (per 100000 adults of population) have been investigated since 2014 to 2016. The Federal State Statistics Service data on population base was used as a basis for the intensive rate estimation. Epidemiological retrospective study was conducted by means of analyzing medical files of patients with primary case definition of chronic myeloid leukemia in the Altai Region. Results and discussion. Primary disease incidence for chronic myeloid leukemia in the Altai Region from 2014 to 2016 made up 20–24 patients per year. The number of primarily detected cases of CML varied from 1.02 to 1.24 per 100 000 adult population annually. The frequency of CML disease detection in urban population figured up to 60 % of the total number of the patients, however the statistically significant differences in intensive rate were not revealed. Male:female ratio corresponded to 49.3 : 50.7 % respectively. The peak of CML disease incidence in the Altai Region accounted for the age of 50-59 years. Median age of patients with primarily defined CML without considering gender was 52 years, whereas median age in women ranged rather higher than in men: 54.3 years old and 49.6 years, respectively. Conclusion. Primary disease incidence for chronic myeloid leukemia in the Altai Region amounts to 1.14 : 100 000 of adult population per year. The disease equally affects men and women. No difference in case incidence has been observed in the urban and rural population, in spite of the territorial peculiarity of the Altai Region (third place in the Russian Federation for rural population numbers; a great number of small population villages, relying mainly on general medical services).
About the Authors
O. V. EfremovaRussian Federation
candidate of medical sciences, assistant of the chair for therapy and general medical practice with the course FVE
656038, Barnaul, Lenin av., 40
656024, Barnaul, Lyapidevskogo str., 1
A. N. Mamaev
Russian Federation
doctor of medical sciences, head of laboratory for hemostasis pathology
656024, Barnaul, Lyapidevskogo str., 1
V. N. Elykomov
Russian Federation
doctor of medical sciences, docent, head of the chair for therapy and general medical practice with the course FVE
656038, Barnaul, Lenin av., 40
References
1. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. М.: Литтерра, 2016. 304 с.
2. Клиническая онкогематология: руководство для врачей / ред. М.А. Волкова. М.: Медицина, 2007. 1120 с.
3. Куликов C.М., Виноградова О.Ю., Челышева Е.Ю., Тищенко И.А., Галайко М.А., Лазарева О.В., Сендерова О.М., Пепеляева В.М., Мересий С.В., Лучинин А.С., Овсепян В.А., Милютина Г.И., Гаврилова Л.В., Авдеева Л.Б., Неверова А.Л., Туркина А.Г. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования в 2009–2012 гг. // Терапевт. арх. 2014. (7). 24–30.
4. Ломаиа Е.Г., Моторин Д.В., Романова Е.Г., Зарицкий А.Ю. Хронический миелолейкоз – до и после применения иматиниба (Часть I) // Онкогематология. 2009. (2). 4–16.
5. Ломаиа Е.Г., Сбитякова Е.И., Лазорко Н.С., Романова Е.Г., Холопова И.В., Никулина Т.С., Зарицкий А.Ю. Рекомендации по диагностике и мониторингу эффективности терапии ХМЛ // Бюл. ФЦСКЭ. 2012. (6). 16–25.
6. Туркина А.Г., Голенков А.К., Напсо Л.И., Крылова И.В., Клиточенко Т.Ю., Сендерова О.М., Ким Н.П. Российский регистр по лечению хронического миелоидного лейкоза в рутинной клинической практике: итоги многолетней работы // Эффектив. фармакотерапия. 2015. (10). 8–13.
7. Туркина А.Г., Зарицкий А.Ю., Шуваев В.А., Челышева Е.Ю., Ломаиа Е.Г., Морозова Е.В., Голенков А.К., Поспелова Т.И., Шухов О.А., Фоминых М.С., Гусарова Г.А., Кузьмина Л.А., Абдуллаев А.О., Мартынкевич И.С. Клинические рекомендации по диагностике и лечению хронического миелолейкоза // Клин. онкогематология. 2017. 10. (3). 294–316.
8. Туркина А.Г., Новицкая Н.В., Голенков А.К., Шуваев В.А., Напсо Л.И., Крылова И.В. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике // Клин. онкогематология. 2017. 10. (3). 390–401.
9. Федеральная служба государственной статистики. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/publications/catalog/doc_1140095700094
10. Cancer research UK. http://www.cancerresearchuk.org/health-professional/cancerstatistics/statistics-by-cancer-type/leukaemia-cml/incidence#ref-
11. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001 // CA Cancer J. Clin. 2001. 51. (1). 15–36.
12. Hoffmann V.S., Lindoerfer D., Thaler J., Boris L., Melanthiou F., Mayer J., Everaus H., Guilhot J., Schubert-Fritschle G., Castagnetti F., Lejniece S., Griskevicius L., Thielen N., Sacha T., Hellmann A., Turkina A.G., Zaritskey A., Bogdanovic A., Indrak K., Zupan I., Steegmann J.L., Simonsson B., Clark R., Hoglund M., Hehlmann R., Hasford J., Baccarani M. Incidence of CML in Europe – a comparison of 19 European countries with US SEER data // Blood. 2014. 124. (21). 3257–3266.
13. Tadwalkar S. The global incidence and prevalence of chronic myeloid leukemia over the next ten years (2017–2027) // Abstr. International Conference on Hematology and Oncology, Bangkok, June 29 – July 1, 2017. https://www.omicsonline.org/abstract/theglobal-incidence-and-prevalence-of-chronic-myeloidleukemia-over-the-next-ten-years-2017-2027/
Review
For citations:
Efremova O.V., Mamaev A.N., Elykomov V.N. PECULIARITIES OF CHRONIC MYELOID LEUKEMIA INCIDENCE IN THE ALTAi krai. Сибирский научный медицинский журнал. 2019;39(2):99-103. (In Russ.) https://doi.org/10.15372/SSMJ20190214